Sesamin inhibits lipopolysaccharide-induced proliferation and invasion through the p38-MAPK and NF-κB signaling pathways in prostate cancer cells.
about
Natural Polyphenols for Prevention and Treatment of CancerSesamin inhibits IL-1β-stimulated inflammatory response in human osteoarthritis chondrocytes by activating Nrf2 signaling pathway.Tianfoshen oral liquid: a CFDA approved clinical traditional Chinese medicine, normalizes major cellular pathways disordered during colorectal carcinogenesis.Phytochemical Contents and Antioxidant and Antiproliferative Activities of Selected Black and White Sesame Seeds.Inhibition of Collagen-Induced Platelet Aggregation by the Secobutanolide Secolincomolide A from Lindera obtusiloba Blume.Chronic diseases, inflammation, and spices: how are they linked?The role of nutrition in influencing mechanisms involved in environmentally mediated diseases.Sesamin from Cuscuta palaestina natural plant extracts: Directions for new prospective applications.
P2860
Q26739022-5BA27CEE-09BC-41A0-9956-290D687D22DAQ37696365-995767D1-888F-4B9F-A05A-98D52FAEC08CQ37716389-8631751E-D860-4C71-98B4-6D2189E54A4CQ38748090-1C2CAFEF-DCC3-453E-9E69-6CBBDD429BB5Q41525756-1BA8D705-D0DA-428B-870F-54D5B500889CQ47647286-B1EA1D25-AD98-48FD-B0F3-D8F034A89B0BQ47704655-B2FE8402-6C37-48F1-BFD4-454468CC69FEQ52596417-E9260279-44F0-4E97-814D-7E7CCDAB54C2
P2860
Sesamin inhibits lipopolysaccharide-induced proliferation and invasion through the p38-MAPK and NF-κB signaling pathways in prostate cancer cells.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Sesamin inhibits lipopolysacch ...... ways in prostate cancer cells.
@en
type
label
Sesamin inhibits lipopolysacch ...... ways in prostate cancer cells.
@en
prefLabel
Sesamin inhibits lipopolysacch ...... ways in prostate cancer cells.
@en
P2093
P356
P1433
P1476
Sesamin inhibits lipopolysacch ...... ways in prostate cancer cells.
@en
P2093
P304
P356
10.3892/OR.2015.3888
P577
2015-03-31T00:00:00Z